/ Zydus Gets Final Approval From USFDA For Memantine Hydrochloride Tablets ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Wednesday, 12 July 2017

Zydus Cadila, in a BSE filing on Wednesday, said that the company has received the final approval from the USFDA to market Memantine Hydrochloride tablets USP, 5 mg and 10 mg.

The drug is used for the treatment of moderate to severe dementia (Alzheimer’s type) and will be produced at the group’s facility in Moraiya, Ahmedabad.

The group now has more than 120 approvals and so far, it has filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Cadila Healthcare was trading at Rs 517.75, up by Rs 0.25 or 0.05 at 1113 hours on Wednesday, on the BSE. The stock had hit an intraday high of Rs 524.70.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 
Give a Missed Call for Free Trial - 09699997717